|
|
Volumn 42, Issue 7, 2002, Pages 774-781
|
|
Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: Implications for combined immunotherapy with interleukin-2
a
b
c
d
e
f
g
h
i
a
j
j
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
HISTAMINE;
INTERLEUKIN 2;
ANTINEOPLASTIC AGENT;
IMMUNOLOGICAL ADJUVANT;
AREA UNDER THE CURVE;
ARTICLE;
BLOOD PRESSURE;
CANCER IMMUNOTHERAPY;
CANCER PATIENT;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG INDUCED DISEASE;
DRUG SAFETY;
HEADACHE;
HEART RATE;
HUMAN;
KIDNEY CARCINOMA;
MELANOMA;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
VASODILATATION;
ADULT;
AGED;
BLOOD;
DRUG COMBINATION;
DRUG INTERACTION;
FEMALE;
INTRAVENOUS DRUG ADMINISTRATION;
KIDNEY TUMOR;
MALE;
METABOLISM;
MIDDLE AGED;
MULTICENTER STUDY;
PATHOLOGY;
SUBCUTANEOUS DRUG ADMINISTRATION;
ADJUVANTS, IMMUNOLOGIC;
ADULT;
AGED;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
DRUG INTERACTIONS;
DRUG THERAPY, COMBINATION;
FEMALE;
HISTAMINE;
HUMAN;
INFUSIONS, INTRAVENOUS;
INJECTIONS, SUBCUTANEOUS;
INTERLEUKIN-2;
KIDNEY NEOPLASMS;
MALE;
MELANOMA;
MIDDLE AGE;
SUPPORT, NON-U.S. GOV'T;
HUMANS;
MIDDLE AGED;
|
|
EID: 0035998755
PISSN: 00912700
EISSN: None
Source Type: Journal
DOI: 10.1177/009127002401102713 Document Type: Article |
|
Times cited : (15)
|
|
References (26)
|
